Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OFIRMEV vs OBETICHOLIC ACID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Obeticholic acid is a potent, selective agonist of the farnesoid X receptor (FXR), a nuclear receptor that regulates bile acid synthesis, transport, and homeostasis. Activation of FXR reduces bile acid synthesis by inhibiting CYP7A1, increases bile acid clearance, and exerts anti-inflammatory and antifibrotic effects.
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
Primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults with inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA,Off-label: Non-alcoholic steatohepatitis (NASH) with fibrosis (not FDA-approved)
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
5 mg orally once daily, may increase to 10 mg once daily if tolerated after 3 months; maximum dose 10 mg daily.
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Terminal elimination half-life is approximately 24 hours (range 14–36 h) in patients with primary biliary cholangitis, allowing once-daily dosing. Steady-state is achieved in about 2 weeks.
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Primarily metabolized by glucuronidation via UGT1A1, UGT1A3, and UGT2B7; undergoes enterohepatic recirculation; minimal CYP450 metabolism.
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
Primarily biliary, with minimal renal excretion (<3%). The drug and its conjugates are eliminated in feces following biliary secretion. Enterohepatic recirculation occurs.
10-25% bound to albumin at therapeutic concentrations.
≥99% bound to serum proteins, primarily albumin.
0.8-1.0 L/kg. Indicates distribution into total body water.
Approximately 0.2–0.4 L/kg, indicating limited extravascular distribution, consistent with a compound undergoing extensive enterohepatic circulation.
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
Oral bioavailability is low (~1–2%) due to extensive first-pass metabolism in the liver. Food may reduce absorption.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m2) or dialysis; use with caution.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B or C: Contraindicated.
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
Safety and efficacy not established in pediatric patients (<18 years).
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
No specific dose adjustment recommended; use standard adult dosing with monitoring for tolerability due to potential age-related decline in hepatic function.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Risk of hepatic decompensation and liver failure in patients with compensated or decompensated cirrhosis (Child-Pugh class B or C). Ocaliva is contraindicated in patients with decompensated cirrhosis or prior hepatic decompensation.
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
Hepatic decompensation and liver failure in cirrhotic patients (Child-Pugh class B or C); not recommended in such patients without appropriate dose adjustment.,Severe pruritus: Manage with antihistamines, bile acid resins, or dose reduction.,Elevation of LDL-cholesterol: Monitor lipid levels and manage according to guidelines.,Dose adjustment required for moderate to severe hepatic impairment (Child-Pugh class B and C).
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
Complete biliary obstruction,Decompensated cirrhosis (Child-Pugh class B or C) or prior hepatic decompensation,Hypersensitivity to obeticholic acid or any excipients
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
No specific food interactions are reported, but alcohol should be avoided due to potential hepatotoxicity. Bile acid binding resins (e.g., cholestyramine) may reduce absorption; separate administration by at least 4-6 hours.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
Animal studies show fetal harm at exposures similar to human therapeutic doses. No adequate human studies. Avoid use in pregnancy unless benefit outweighs risk. First trimester: potential for teratogenicity. Second/third trimester: risk of fetal bile acid toxicity.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
Excretion in human milk unknown. Due to potential for serious adverse reactions in nursing infants, decision should be made to discontinue nursing or drug. M/P ratio not determined.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
No dose adjustment recommendations established. Pregnancy may alter bile acid metabolism; consider lower starting dose due to potential for increased systemic exposure from altered hepatic transport.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
Obeticholic acid is a farnesoid X receptor agonist used for primary biliary cholangitis (PBC). It increases bile acid excretion and may cause dose-dependent pruritus; start at 5 mg daily and titrate to 10 mg if tolerated. Monitor hepatic function closely due to risk of liver decompensation. Contraindicated in patients with complete biliary obstruction.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
Take obeticholic acid exactly as prescribed, usually once daily with or without food.,Common side effects include itching (pruritus), which may be severe; inform your doctor if it becomes bothersome.,Report any symptoms of liver problems such as jaundice, dark urine, or abdominal pain immediately.,Avoid alcohol while taking this medication.,Do not take additional bile acid binding resins (e.g., cholestyramine) within 4-6 hours of obeticholic acid.,Inform your healthcare provider of all other medications you are taking, especially warfarin or other blood thinners.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before starting this medication.
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OFIRMEV vs OBETICHOLIC ACID, answered by our medical review team.
OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. OBETICHOLIC ACID is a Farnesoid X receptor agonist that works by Obeticholic acid is a potent, selective agonist of the farnesoid X receptor (FXR), a nuclear receptor that regulates bile acid synthesis, transport, and homeostasis. Activation of FXR reduces bile acid synthesis by inhibiting CYP7A1, increases bile acid clearance, and exerts anti-inflammatory and antifibrotic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OFIRMEV and OBETICHOLIC ACID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. The standard adult dose of OBETICHOLIC ACID is: 5 mg orally once daily, may increase to 10 mg once daily if tolerated after 3 months; maximum dose 10 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OFIRMEV and OBETICHOLIC ACID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. OBETICHOLIC ACID is classified as Category C. Animal studies show fetal harm at exposures similar to human therapeutic doses. No adequate human studies. Avoid use in pregnancy unless benefit outweighs risk. First trimester: po. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.